Christine DO CAO

Dr. Christine DO CAO


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AJArnaud JANNIN
Arnaud JANNIN
AEAlexandre Escande
Alexandre Escande
AGAbir Al Ghuzlan
Abir Al Ghuzlan
PBPierre Blanchard
Pierre Blanchard
DHDana M. Hartl
Dana M. Hartl
JHJulien Hadoux
Julien Hadoux
Anaplastic thyroid carcinoma (ATC) is a rare and undifferentiated form of thyroid cancer. Its prognosis is poor: the median overall survival (OS) of patients varies from 4 to 10 months after diagnosis. However, a doubling of the OS time may be possible owing to a more systematic use of molecular tests for targeted therapies and integration of fast-track dedicated care pathways for these patients in tertiary centers. The diagnostic confirmation, if needed, requires an urgent biopsy reread by an expert pathologist with additional immunohistochemical and molecular analyses. Therapeutic management, defined in multidisciplinary meetings, respecting the patient’s choice, must start within days following diagnosis. For localized disease diagnosed after primary surgical treatment, adjuvant chemo-radiotherapy is recommended. In the event of locally advanced or metastatic disease, the prognosis is very poor. Treatment should then involve chemotherapy or targeted therapy and decompressive cervical radiotherapy. Here we will review current knowledge on ATC and provide perspectives to improve the management of this deadly disease.

1 September 2019 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
AJArnaud JANNIN
Arnaud JANNIN
NPNicolas Penel
Nicolas Penel
MLMiriam Ladsous
Miriam Ladsous
MVMarie Christine Vantyghem
Marie Christine Vantyghem
CCChristine DO CAO
Christine DO CAO

1 May 2015 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
CCChristine DO CAO
Christine DO CAO
SASébastien Aubert
Sébastien Aubert
CTClémentine Trinel
Clémentine Trinel
MOMarie Françoise Odou
Marie Françoise Odou
MBMichael Bayaram
Michael Bayaram
MPMartine Patey
Martine Patey

1 February 2015 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
CCChristine DO CAO
Christine DO CAO
JWJ.-L. Wémeau
J.-L. Wémeau

1 December 2015 in Thyroid®
Verified
Journal Article
Closed access
SEStéphanie Espiard
Stéphanie Espiard
GPGregory Petyt
Gregory Petyt
GLGeorges Lion
Georges Lion
ABAmandine Béron
Amandine Béron
CCChristine DO CAO
Christine DO CAO
RCRobert Caiazzo
Robert Caiazzo
Over the past decade, transaxillary robot-assisted thyroidectomy (TRAT) has played a growing role in the management of thyroid nodules. Despite thousands of patients being operated on in Asia for a long time, a few cases of subcutaneous thyroid tissue (STI) have recently been described in the literature, relating to new palpable mass being discovered several years after the original endoscopic thyroidectomy surgery. The high dose radioiodine therapy performed in two patients of a series of 19 patients allowed us to discover precociously microscopic SIT. STI after TRAT could be more common than it currently is, if we consider ectopic tissue uptake with high dose RIT. Despite the use of an endobag for extraction, the dissemination due to thyroid capsule rupture after indelicate robotic manipulation is probably the cause, especially because of the size of the nodules and the lack of experience of beginner surgeons. Hence, until dedicated robotic surgeons acquire a sufficient level of technical experience, and according to the indication of intervention (e.g. thyroid volume), long-term follow-up should be proposed for patients who have not had RIT, in order to reveal if these SITs could lead later to an ectopic thyroid mass and its putative oncologic consequences in the context of thyroid cancer cells dissemination.

1 October 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
HTHélène Tisset
Hélène Tisset
Nassim KamarNassim Kamar
Nassim Kamar
IFIsabelle Faugeron
Isabelle Faugeron
PRPascal Roy
Pascal Roy
CPClaire Pouteil-Noble
Claire Pouteil-Noble
TNThe Tuthyref Network
The Tuthyref Network
Context:An increased cancer mortality is reported in transplanted patients. Objective:This multicentric study aimed to investigate the rate of thyroid cancer recurrence after transplantation. Results:Sixty-eight patients (35 male/33 female) with a history of both thyroid cancer and organ transplantation were recruited via two nationwide French networks. Histological analysis identified 58 papillary (88%), 5 follicular (7.5%), and 3 poorly differentiated cancer cases (4.5 %). Thirty-one patients (52%) presented high recurrence risk tumors. In the 36 patients with thyroid cancer diagnosed after transplantation, the 5-year disease-free survival (DFS) was 74.7% (SE: 7.3%). One patient died after progression of a poorly differentiated cancer. Persistent disease was observed in six high-risk patients. One of them underwent a second transplantation and disease remained stable after 5 years of follow-up. Thyroid cancer had been diagnosed before transplantation in 32 patients. One patient with cystic fibrosis and thyroid lung metastases at the time of lung transplantation underwent a 4-year remission. For the 31 patients in remission at the time of transplantation, the 5-year DFS was 93.1% (SE: 4.8%). Two patients with local recurrence presented subsequent remission. For the entire study population, the 5-year and 9-year DFS were 81.9% (SE: 5.5%) and 75.6% (SE: 7.9%), respectively. Recurrence or persistent disease occurred in patients with high-risk tumors. Conclusions:The prognosis of thyroid cancer does not seem to be altered by transplantation. This suggests that a history of thyroid cancer should not be considered a contraindication.